CLINICAL STUDY OF TA-058

Abstract

A new antibacterial agent, TA-058, was administered to 6 patients including 2 cases of pneumonia, one case of acute bronchitis, 2 cases of acute cholecystitis and one case of chronic pyelonephritis. TA-058 was given by I. V. D. infusion at a daily dose of 2-4 g for 3. 5-10 days. Clinical efficacy was excellent in one (acute cholecystitis), good in one (acute cholecystitis), fair in 2 (pneumonia, chronic pyelonephritis), poor in one (acute bronchitis) and undetermined in one (pneumonia). No side effects were observed.